Positive Results from Pivotal Trials of CASGEVY™ (exa

- Longer-term follow-up data demonstrate consistent and durable response to treatment -BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced two oral presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition from the global pivotal trials of CASGEVY...

Related Keywords

Saudi Arabia , United Kingdom , London , City Of , United States , Boston , Massachusetts , Bahrain , Australia , Great Britain , Saudi , American , America , Manisha Pai , Heather Nichols , Exagamglogene Autotemcel , Carmen Bozic , Occlusive Crisis On Health , National Health Regulatory Authority , Facebook , Drug Administration , Regulatory Agency , Improvements In Health , Vertex Pharmaceuticals Incorporated , Drug Agency , Linkedin , Companies To Work , Exchange Commission , European Medicines Agency , Vertex Pharmaceuticals Incorporated Nasdaq , Instagram , Youtube , American Society Of Hematology , Global Medicines Development , American Society , Annual Meeting , Executive Vice President , Medical Affairs , Chief Medical Officer , Prescription Drug User Fee Act , Severe Sickle Cell , Health Related Quality , Life After Exagamglogene Autotemcel , Transfusion Dependent Beta , Patients With Severe Sickle Cell , Status Among Patients , Cohort Study , Recent Vaso Occlusive Crisis , Sickle Cell , Sickle Cell Disease Prevalence , Model Using , Foreign Born State Specific Population , Sickle Cell Disease , Transfusion Dependent Beta Thalassemia , Saudi Food , Prescribing Information , Patient Information , North America , Top Employers , Private Securities Litigation Reform Act ,